ReviewClinical rheumatology2016
ASAS classification criteria for axial spondyloarthritis: time to modify.
Review in Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- The prevalence of sarcopenia in spondyloarthritis patients: a meta-analysis.Arthritis research & therapy · 2024Pooled it
- A guideline on biomarkers in the diagnosis and evaluation in axial spondyloarthritis.Frontiers in immunology · 2024Guideline
- Central Sensitization in Spondyloarthritis: Implications for Personalized Medicine.Journal of personalized medicine · 2026Article
- Nationwide study of spondyloarthritis spectrum and disease characteristics in Egypt.Scientific reports · 2025Article
- Retrospective Analysis of Spinal Radiographs for the Presence of Lumbosacral Transitional Vertebra in Patients with Axial Spondyloarthritis.Archives of rheumatology · 2025Article
- Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.Immunity, inflammation and disease · 2023Article
- Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis.Advances in rheumatology (London, England) · 2023Observational
- Re-stooping after Corrective Osteotomy in Patients with Ankylosing Spondylitis.Clinics in orthopedic surgery · 2023Article
- Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.Qatar medical journal · 2022Article
- Therapeutic Potential of Triptolide in Treating Bone-Related Disorders.Frontiers in pharmacology · 2022Review
- Development and test-retest reliability of a screening tool for axial spondyloarthritis.PloS one · 2022Article
- Article
- The journey of the non-radiographic axial spondyloarthritis patient: the perspective of professionals and patients.Clinical rheumatology · 2021Article
- Elevated Serum D-Dimer May Reflect the Presence of Gut Inflammation in Spondyloarthritis.Frontiers in medicine · 2021Article
- Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis.ImmunoTargets and therapy · 2021Review
- Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases.Inflammatory intestinal diseases · 2020Article
- Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy.Rheumatology and therapy · 2019Review
- Unmet Needs in Axial Spondyloarthritis.Clinical reviews in allergy & immunology · 2018Review
- Radiologic approach to axial spondyloarthritis: where are we now and where are we heading?Rheumatology international · 2018Review
- Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria.Therapeutic advances in musculoskeletal disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between ankylosing spondylitis and the recently proposed entity called axial spondyloarthritis with its radiographic and non-radiographic forms that have been defined by the Assessment of Spondyloarthritis International Society (ASAS) criteria for axial spondyloarthritis (axSpA), is currently being debated. The Food and Drug Agency (FDA) had criticized the ASAS criteria and the studies which used these criteria to enroll patients in a clinical trial of certolizumab and adalimumab for the treatment of non-radiographic axial spondyloarthritis. The primary aim of classification criteria is to create homogenous patient populations for basic and clinical research. But the multi-arm construct of the ASAS criteria is a potential source of heterogeneity reducing their utility. Criteria sets should be regarded as dynamic concepts open to modifications or updates as our knowledge advances. We provide evidence to conclude that it is time to modify the ASAS Criteria for axSpA, and we propose some of the steps that can be taken to start moving forward in improving the validity of these criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.